A recording of our NRG-RTOG0848 Webinar is now posted. Please forward to 3:40 for video due to technical difficulties. Read more
NRG Oncology Newsletter Volume 2 2017 is now available. Read more
Dr. Wolmark recipient of 2017 Giants of Cancer Care® award in breast cancer. Read more
NRG Oncology is seeking an experienced, full-time Executive Director in Philadelphia, PA. Read more
NRG Oncology 2017 ASCO Annual Meeting presentations. Read more
NEJM releases new Common Rule regarding federal regulations for the ethical conduct of human subject research. Read more
Anti-androgen Therapy in Addition to Radiation Therapy Improves Long-term Survival for Men with Recurrent or Persistent Prostate Cancer. Read more
NRG Oncology Researchers Develop Improved Model to Predict Glioblastoma Patients’ Response to Radiation Temozolomide Chemotherapy. Read more
NRG Oncology Newsletter Volume 1 2017 is now available. Read more
NRG-LU001 Reaches Patient Accrual Goal. Read more
Results of NRG-NSABP B-52 presented by Mothaffar Rimawi, MD at 2016 SABCS. Read more
Terry Mamounas, MD, presented initial results of NRG-NSABP B-42 at 2016 SABCS. Read more
Drs. Bruner and Gillison Elected to National Academy of Medicine. Read the article.
Douglas W. Arthur, MD discusses breast preserving surgery on NRG-RTOG 1014 in an interview with the ASCO Post. Watch the video
Deborah Watkins Bruner, RN, PhD presented "Hypofractionated RT Can Reduce Treatment Time by One-third with Comparable QOL for Prostate Cancer Patients" at ASTRO Annual Meeting. View the slides
Bradley R. Prestidge, MD, MS presented "Intermediate Risk Prostate Cancer May be Well Controlled with Brachytherapy Alone" at ASTRO Annual Meeting. View the slides
Intensity Modulated Radiation Therapy Associated with Reduction in Patient Reported Xerostomia in Head and Neck Cancer Patients. Read more
IDH and CIC Mutations Provide Prognostic Information for Grade II and III Gliomas. Read more
The Addition of External Beam Therapy to Brachytherapy Does Not Produce Superior Progression-Free Survival Results for Intermediate Risk Prostate Cancer Patients. Read more